Evidence map›Paper›PMID 29701222›Full record

ArticlePhotochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology2018

Progressive cationic functionalization of chlorin derivatives for antimicrobial photodynamic inactivation and related vancomycin conjugates.

Liyi Huang, Min Wang, Ying-Ying Huang, Ahmed El-Hussein, Lawrence M Wolf, Long Y Chiang, Michael R Hamblin

Abstract read
In one paragraph

Article in Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Putting a "CPharmaceuticals (Basel, Switzerland) · 2023
    Article
  5. Article
  6. Photoinactivation of Yeast and Biofilm Communities ofJournal of fungi (Basel, Switzerland) · 2022
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Fullerenes as photosensitizers in photodynamic therapy: pros and cons.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Liyi HuangWellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. hamblin@helix.mgh.harvard.edu and Department of Dermatology, Harvard Medical School, Boston, Massachusetts 02115, USA.
Min WangDepartment of Chemistry, University of Massachusetts Lowell, Lowell, Massachusetts 01854, USA. Long_Chiang@uml.edu.
Ying-Ying HuangWellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. hamblin@helix.mgh.harvard.edu and Department of Dermatology, Harvard Medical School, Boston, Massachusetts 02115, USA.
Ahmed El-HusseinWellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. hamblin@helix.mgh.harvard.edu and Department of Dermatology, Harvard Medical School, Boston, Massachusetts 02115, USA and The National Institute of Laser Enhanced Science (NILES), Cairo University, Egypt.ORCID http://orcid.org/0000-0002-6349-3282
Lawrence M WolfDepartment of Chemistry, University of Massachusetts Lowell, Lowell, Massachusetts 01854, USA. Long_Chiang@uml.edu.
Long Y ChiangDepartment of Chemistry, University of Massachusetts Lowell, Lowell, Massachusetts 01854, USA. Long_Chiang@uml.edu.
Michael R HamblinWellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. hamblin@helix.mgh.harvard.edu and Department of Dermatology, Harvard Medical School, Boston, Massachusetts 02115, USA and Harvard-MIT Division of Health Sciences and Technology, Cambridge, Massachusetts 02139, USA.ORCID http://orcid.org/0000-0001-6431-4605
University of Massachusetts Lowell · USHarvard University · USMassachusetts General Hospital · US

Funding

Photodynamic Therapy of Localized InfectionsR01AI050875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2003 to 2017
$4.8M
Synergistic Photodynamic Therapy for Catherer-Associated Urinary Tract InfectionsR21AI121700 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2016 to 2017
$462k
NIAID NIH HHS R01 AI050875NIAID NIH HHS R21 AI121700
6 · The paper itself

Abstract

It is known that multiple cationic charges are required to produce broad-spectrum antimicrobial photosensitizers (PS) for photodynamic inactivation (aPDI) or photodynamic therapy of bacteria and fungi. In the present study we describe the synthesis and aPDI testing of a set of derivatives prepared from the parent pheophytin molecule with different numbers of attached side arms (1-3) each consisting of five quaternized cationic groups (pentacationic), producing the corresponding [Zn2+]pheophorbide-a-N(C2N+C1C3)5 (Zn-Phe-N5+, 5 charges), [Zn2+]chlorin e6-[N(C2N+C1C3)5]2 (Zn-Chl-N10+, 10 charges) and [Zn2+]mesochlorin e6-[N(C2N+C1C3)5]3 (Zn-mChl-N15+, 15 charges). Moreover, a conjugate between Zn-Phe-N5+ and the antibiotic vancomycin called Van-[Zn2+]-m-pheophorbide-N(C2N+C1C3)5 (Van-Zn-mPhe-N5+) was also prepared. The aPDI activities of all compounds were based on Type-II photochemistry (1O2 generation). We tested these compounds against Gram-positive methicillin-resistant Staphylococcus aureus (MRSA), Gram-negative Escherichia coli, and the fungal yeast Candida albicans. All three compounds were highly active against MRSA, giving eradication (≥6 logs of killing) with <1.0 μM and 10 J cm-2 of 415 nm light. The order of activity was Zn-Phe-N5+ > Zn-Chl-N10+ > Zn-mChl-N15+. In the case of E coli the activity was much lower (eradication was only possible with 50 μM Zn-mChl-N15+ and 20 J cm-2). The order of activity was the reverse of that found with MRSA (Zn-mChl-N15+ > Zn-Chl-N10+ > Zn-Phe-N5+). Activity against C. albicans was similar to E. coli with Zn-mChl-N15+ giving eradication. The activity of Van-Zn-mPhe-N5+ was generally lower than that of Zn-Phe-N5+ (except for E. coli). Red (660 nm) light was also effective as might be expected from the absorption spectra. An initial finding that Van-Zn-mPhe-N5+ might have higher activity against vancomycin resistant Enterococcus fecium (VRE) strains (compared to vancomycin sensitive strains) was disproved when it was found that VRE strains were also more sensitive to aPDI with Zn-Phe-N5+. The minimum inhibitory concentrations of Van-Zn-mPhe-N5+ were higher than those of Van alone, showing that the antibiotic properties of the Van moiety were lessened in the conjugate. In conclusion, Zn-Phe-N5+ is a highly active PS against Gram-positive species and deserves further testing. Increasing the number of cationic charges increased aPDI efficacy on C. albicans and Gram-negative E. coli.

Indexed as

Anti-Bacterial AgentsAntifungal AgentsCandida albicansCationsDose-Response Relationship, DrugGram-Negative BacteriaGram-Positive BacteriaMicrobial Sensitivity TestsOrganometallic CompoundsPhotochemotherapyPorphyrinsQuantum TheoryReactive Oxygen SpeciesStructure-Activity RelationshipVancomycinZincAnti-Bacterial AgentsAntifungal AgentsCationschlorinOrganometallic CompoundsPorphyrinsReactive Oxygen SpeciesVancomycinZinc

Identifiers

PMID29701222
PMCPMC5955822
OpenAlexW2797647389

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.